Stockreport

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Solid Biosciences Inc.  (SLDB) 
Last solid biosciences inc. earnings: 8/14 07:25 am Check Earnings Report
US:NASDAQ Investor Relations: investors.solidbio.com/investor-relations
PDF - SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been com [Read more]